menu

How Do I Optimize Use of Non-Cellular CD19-Targeted Therapies in R/R DLBCL?

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Optimizing CD19-Targeted Therapies in Relapsed and Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

How Do I Optimize Use of Non-Cellular CD19-Targeted Therapies in R/R DLBCL?

Minute CME/CE™
ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Take 1 Minute Challenge
1 Minute Challenge Completed
1.00 credits
Completing the pre-test is required to view this content.
Completing the pre-survey is required to view this content.
Details
Episodes
Presenters
Documents
Comments
  • Overview

    There is a substantial need for hematology/oncology clinicians to review the latest data on CD19-targeted therapies for R/R DLBCL. This program highlights the science and mechanisms of actions, results from landmark clinical trials, and management of side effects of the available options. Expert insights can aid clinical decision-making when clinical data are limited or emerging. Notably, the place of the non-cellular CD19-targeted therapies can present a challenge to clinicians, especially for those patients who are being considered for CD19-CAR T-cell therapy.

  • Target Audience

    This activity is designed to meet the educational needs of hematologists/oncologists, nurses, pharmacists and other members of the interprofessional team who are involved in the management of patients with Diffuse Large B-Cell Lymphoma (DLBCL).

  • Learning Objectives

    After participating in this educational activity, participants should be better able to: 

    1. Evaluate recent clinical trial data for current and emerging CD19-directed monoclonal antibody therapies and combinations for the treatment of R/R DLBCL across lines of therapy
    2. Evaluate recent clinical trial data for current and emerging CD19-directed cellular therapies and combinations for the treatment of R/R DLBCL across lines of therapy
    3. Implement recent evidence and best practices for monitoring and mitigating adverse events associated with CD19-directed therapeutic regimens used in the treatment of patients with DLBCL
  • Accreditation and Credit Designation Statements

    In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC) and TotalCME, Inc. GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

  • Faculty Disclosure of Commercial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. 
    The following faculty have reported relationships with ineligible companies:

    Paolo F. Caimi, MD, faculty for this educational event, is a contract researcher for Genentech, and ADC Therapeutics; and receives consulting fees from ADC Therapeutics, Genentech, Gilead, Incyte, Bristol Myers Squibb, Takeda, Lilly, MEI Pharma, Novartis, and Genmab. 

    Peter Riedell, MD, faculty for this educational event, is a contract researcher for Bristol Myers Squibb, Kite Pharma, Inc/Gilead, MorphoSys, Calibr, Tessa Therapeutics, Fate Therapeutics, Xencor, and Novartis; and receives consulting fees from AbbVie, ADC Therapeutics, Novartis Pharmaceuticals Corporation, Bristol Myers Squibb, Janssen, BeiGene, Karyopharm Therapeutics Inc., Takeda Pharmaceutical Company, Kite Pharma, Inc./Gilead, Sana Biotechnology, Nektar Therapeutics, Nurix Therapeutics, Intellia Therapeutics, and CVS Caremark.

  • Planners and Managers Disclosure List

    The following planners/reviewers have reported no relationships with ineligible companies:

    Robert Garris, PharmD, MPH, planner for this educational event, has no relevant financial relationships with ineligible companies.

    William Mencia, MD, FACEHP, CHCP, planner for this educational event, has no relevant financial relationships with ineligible companies.

    All the relevant financial relationships for these individuals have been mitigated.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and TotalCME, Inc. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of MedEd On The Go you are subject to the terms and conditions of use, including copyright and licensing restrictions of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • Acknowledgment

    This activity is supported by independent educational grants from Bristol Myers Squibb and ADC Therapeutics America, Inc.

    Jointly provided by Global Learning Collaborative (GLC) and TotalCME, Inc.

  • Fee Statement

    This activity is FREE to all participants.

  • Instructions

    During the period 9/30/2022 through 9/30/2023, registered participants wishing to receive continuing education credit for this activity must follow these steps:
    1. Read the learning objectives and faculty disclosures.
    2. Answer a pre-program question.
    3. View the program.
    4. Complete the post-test with a score of 100%. 
    5. Complete activity evaluation.
    6. Apply for credit and either bank your credits or print your certificate.

    For Pharmacists: Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Customize your experience based on your profession
Profession
Registration is a short process and your information will be kept safe.
Schedule6 Dec 2022